search
Back to results

NOVAPAK Nasal Packing in Shellfish Allergic Patients

Primary Purpose

Shellfish Hypersensitivity, Epistaxis

Status
Not yet recruiting
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
NOVAPAK nasal packing applied to forearm
NOVAPAK nasal packing applied to nasal cavity
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Shellfish Hypersensitivity focused on measuring nasal bleedings, Post-surgical healing, chitosan-based films

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults aged 18-60
  • Positive history of shellfish allergy
  • Confirmation of allergy via previous reaction during oral challenge or convincing clinical history and testing.

Exclusion Criteria:

  • Severe lung diseases: severe asthma, obstructive lung disease
  • Severe cardiovascular disease: history of congestive heart failure, myocardial infarction, valvulopathy, or unstable tachy-or-bradyarrhythmia.
  • Severe cerebrovascular disease: history of stroke or severe carotid stenosis.
  • Presence of beta-blocker mediations.
  • Patients unable to discontinue antihistamine medications or prednisone.
  • Patients with severe or refractory anaphylaxis during prior oral challenge to shellfish, or those with documented systemic mastocytosis.
  • Pregnancy

Sites / Locations

  • St. Joseph's Health Care

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Study arm

Arm Description

Stage 1 After shellfish allergy is confirmed through the skin prick test and IgE analysis, Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm. Participants will then be monitored for 1 hour, and any- reaction will be documented. In case of any symptoms of an allergic reaction, their study participation will be terminated. Stage 2 If no allergic symptoms are observed in stage 1, the patient's nose will be anesthetized with topical lidocaine. A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes. After removal, the participant will be monitored in the clinic for an hour. Any allergic reaction will be documented, including increased nasal congestion, rhinorrhea, or pruritis.

Outcomes

Primary Outcome Measures

First stage - Skin test
The occurrence of an Allergic reaction to Novapak packing in the anterior aspect of the patients' non-dominant arm will be tested.
Second stage - Novapak in the nasal cavity (1 hour)
The occurrence of Allergic reaction to Novapak packing on the participant's nasal cavity at the level of the inferior turbinate.
Second stage - Novapak in the nasal cavity (48 hours)
The occurrence of Allergic reaction to Novapak packing on the participant's nasal cavity at the level of the inferior turbinate.

Secondary Outcome Measures

Change in Nasal congestion score - (1 hour)
Change on the nasal congestion score 1 hour after the provocation challenge in the nose using NOVAPAK 0 =No congestion =Mild congestion =Moderate congestion =Severe congestion
Change in Nasal congestion score - (48 hours)
Change on the nasal congestion score 48 hours after the provocation challenge in the nose using NOVAPAK 0 =No congestion =Mild congestion =Moderate congestion =Severe congestion

Full Information

First Posted
April 5, 2022
Last Updated
September 7, 2023
Sponsor
Lawson Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05343650
Brief Title
NOVAPAK Nasal Packing in Shellfish Allergic Patients
Official Title
NOVAPAK Nasal Packing: Safety Study in Shellfish Allergic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 15, 2024 (Anticipated)
Primary Completion Date
December 24, 2024 (Anticipated)
Study Completion Date
May 15, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lawson Health Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
NOVAPAK is a sponge-like material made from materials found in shellfish. It is commonly used after nasal surgery or in nasal bleeding, as it promotes healing, decreases bleeding, and has antibacterial properties. Although NOVOPAK does not contain proteins or compounds known to be responsible for allergic reactions in people with a known allergy to shellfish, out of an abundance of caution, the manufacturer (Medtronic) has recommended avoidance in those with known shellfish allergy. There have been no reported allergic reactions in patients with shellfish allergy who were given chitosan bandages in emergencies (e.g. military applications). The study aims to investigate the safety of its use in patients with known shellfish allergy to improve healthcare quality and patient care support.
Detailed Description
This is a prospective interventional study to assess whether the tested product triggers an allergic reaction in patients with known-shellfish allergies. The primary objective is to assess the safety of Novapak, a chitosan-containing nasal packing material, in patients with known shellfish allergy. The study will be conducted in two phases. First, participants will undergo an allergy test - Skin prick test (SPT) to crab, lobster, shrimp, oyster, clam, scallop, squid, and octopus -, and antibody levels analysis. Second, in a controlled setting (i.e., in a hospital clinic that includes a resuscitation cart and doctors monitoring - allergist and otolaryngologist), Novapak packing will be applied to the patient's skin for 30 minutes (on the anterior aspect of the patients' non-dominant arm). Then, provided that no allergic symptoms are observed in stage 1, the patient's nose will be anesthetized with topical lidocaine, and a piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes. After removal, the participant will be monitored in the clinic for an hour. Any allergic reaction will be documented, including increased nasal congestion, rhinorrhea, or pruritis. Since Novapak contains purified chitosan, the investigators hypothesizes that no allergic reactions will be demonstrated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Shellfish Hypersensitivity, Epistaxis
Keywords
nasal bleedings, Post-surgical healing, chitosan-based films

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
prospective interventional study
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Study arm
Arm Type
Experimental
Arm Description
Stage 1 After shellfish allergy is confirmed through the skin prick test and IgE analysis, Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm. Participants will then be monitored for 1 hour, and any- reaction will be documented. In case of any symptoms of an allergic reaction, their study participation will be terminated. Stage 2 If no allergic symptoms are observed in stage 1, the patient's nose will be anesthetized with topical lidocaine. A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes. After removal, the participant will be monitored in the clinic for an hour. Any allergic reaction will be documented, including increased nasal congestion, rhinorrhea, or pruritis.
Intervention Type
Device
Intervention Name(s)
NOVAPAK nasal packing applied to forearm
Intervention Description
Novapak packing will be applied to the patient's skin for 30 minutes on the anterior aspect of the patients' non-dominant arm. In case of pre-existing wounds, it will be applied to the other forearm.
Intervention Type
Device
Intervention Name(s)
NOVAPAK nasal packing applied to nasal cavity
Intervention Description
A piece of Novapak material will be applied to the participant's nasal cavity at the level of the inferior turbinate for 15 minutes
Primary Outcome Measure Information:
Title
First stage - Skin test
Description
The occurrence of an Allergic reaction to Novapak packing in the anterior aspect of the patients' non-dominant arm will be tested.
Time Frame
Until one hour after the test.
Title
Second stage - Novapak in the nasal cavity (1 hour)
Description
The occurrence of Allergic reaction to Novapak packing on the participant's nasal cavity at the level of the inferior turbinate.
Time Frame
Until one hour after the test
Title
Second stage - Novapak in the nasal cavity (48 hours)
Description
The occurrence of Allergic reaction to Novapak packing on the participant's nasal cavity at the level of the inferior turbinate.
Time Frame
48 hours after the test.
Secondary Outcome Measure Information:
Title
Change in Nasal congestion score - (1 hour)
Description
Change on the nasal congestion score 1 hour after the provocation challenge in the nose using NOVAPAK 0 =No congestion =Mild congestion =Moderate congestion =Severe congestion
Time Frame
Baseline, 1 hour after the provocation challenge.
Title
Change in Nasal congestion score - (48 hours)
Description
Change on the nasal congestion score 48 hours after the provocation challenge in the nose using NOVAPAK 0 =No congestion =Mild congestion =Moderate congestion =Severe congestion
Time Frame
Baseline, 48 hours after the provocation challenge.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults aged 18-60 Positive history of shellfish allergy Confirmation of allergy via previous reaction during oral challenge or convincing clinical history and testing. Exclusion Criteria: Severe lung diseases: severe asthma, obstructive lung disease Severe cardiovascular disease: history of congestive heart failure, myocardial infarction, valvulopathy, or unstable tachy-or-bradyarrhythmia. Severe cerebrovascular disease: history of stroke or severe carotid stenosis. Presence of beta-blocker mediations. Patients unable to discontinue antihistamine medications or prednisone. Patients with severe or refractory anaphylaxis during prior oral challenge to shellfish, or those with documented systemic mastocytosis. Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Leigh J Sowerby, MD
Phone
+15196466143
Email
rhinologyclinic@sjhc.london.on.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Taciano Rocha, Ph.D.
Phone
+15196466100
Ext
61125
Email
taciano.rocha@sjhc.london.on.ca
Facility Information:
Facility Name
St. Joseph's Health Care
City
London
State/Province
Ontario
ZIP/Postal Code
N5A 4V2
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16532368
Citation
Kurita K. Chitin and chitosan: functional biopolymers from marine crustaceans. Mar Biotechnol (NY). 2006 May-Jun;8(3):203-26. doi: 10.1007/s10126-005-0097-5. Epub 2006 Mar 17.
Results Reference
background
PubMed Identifier
12615058
Citation
Chou TC, Fu E, Wu CJ, Yeh JH. Chitosan enhances platelet adhesion and aggregation. Biochem Biophys Res Commun. 2003 Mar 14;302(3):480-3. doi: 10.1016/s0006-291x(03)00173-6.
Results Reference
background
PubMed Identifier
8978649
Citation
Rao SB, Sharma CP. Use of chitosan as a biomaterial: studies on its safety and hemostatic potential. J Biomed Mater Res. 1997 Jan;34(1):21-8. doi: 10.1002/(sici)1097-4636(199701)34:13.0.co;2-p.
Results Reference
background
PubMed Identifier
31558059
Citation
Winebrake JP, Mahrous A, Kacker A, Tabaee A, Levinger JI, Pearlman AN, Stewart MG, Lelli GJ Jr. Postoperative Bioresorbable Chitosan-Based Dressing for Endoscopic Middle Meatal Dacryocystorhinostomy With Balloon Dilation. Ear Nose Throat J. 2021 Jul;100(6):425-429. doi: 10.1177/0145561319866822. Epub 2019 Sep 26.
Results Reference
background
PubMed Identifier
28456847
Citation
Zhou JC, Zhang JJ, Zhang W, Ke ZY, Zhang B. Efficacy of chitosan dressing on endoscopic sinus surgery: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2017 Sep;274(9):3269-3274. doi: 10.1007/s00405-017-4584-x. Epub 2017 Apr 29.
Results Reference
background
PubMed Identifier
22925096
Citation
Kourelis K, Shikani AH. Effectiveness of chitosan-based packing in 35 patients with recalcitrant epistaxis in the context of coagulopathy. Clin Otolaryngol. 2012 Aug;37(4):309-13. doi: 10.1111/j.1749-4486.2012.02488.x. No abstract available.
Results Reference
background
PubMed Identifier
20109331
Citation
Valentine R, Athanasiadis T, Moratti S, Hanton L, Robinson S, Wormald PJ. The efficacy of a novel chitosan gel on hemostasis and wound healing after endoscopic sinus surgery. Am J Rhinol Allergy. 2010 Jan-Feb;24(1):70-5. doi: 10.2500/ajra.2010.24.3422.
Results Reference
background
Citation
HemCon® Bandage PRO - Tricol Biomedical [Internet]. [cited 2021 Dec 28]. Available from: https://tricolbiomedical.com/product/hemcon-bandage-pro/
Results Reference
background
PubMed Identifier
22128651
Citation
Waibel KH, Haney B, Moore M, Whisman B, Gomez R. Safety of chitosan bandages in shellfish allergic patients. Mil Med. 2011 Oct;176(10):1153-6. doi: 10.7205/milmed-d-11-00150.
Results Reference
background
PubMed Identifier
27009439
Citation
Amaral L, Silva D, Couto M, Nunes C, Rocha SM, Coimbra MA, Coimbra A, Moreira A. Safety of chitosan processed wine in shrimp allergic patients. Ann Allergy Asthma Immunol. 2016 May;116(5):462-3. doi: 10.1016/j.anai.2016.02.004. Epub 2016 Mar 19. No abstract available.
Results Reference
background
PubMed Identifier
15241360
Citation
Sicherer SH, Munoz-Furlong A, Sampson HA. Prevalence of seafood allergy in the United States determined by a random telephone survey. J Allergy Clin Immunol. 2004 Jul;114(1):159-65. doi: 10.1016/j.jaci.2004.04.018.
Results Reference
background
PubMed Identifier
27613460
Citation
Moonesinghe H, Mackenzie H, Venter C, Kilburn S, Turner P, Weir K, Dean T. Prevalence of fish and shellfish allergy: A systematic review. Ann Allergy Asthma Immunol. 2016 Sep;117(3):264-272.e4. doi: 10.1016/j.anai.2016.07.015.
Results Reference
background
PubMed Identifier
23575656
Citation
Lopata AL, Jeebhay MF. Airborne seafood allergens as a cause of occupational allergy and asthma. Curr Allergy Asthma Rep. 2013 Jun;13(3):288-97. doi: 10.1007/s11882-013-0347-y.
Results Reference
background
PubMed Identifier
34489219
Citation
Gelis S, Rueda M, Pascal M, Fernandez-Caldas E, Fernandez EA, Araujo-Sanchez G, Bartra J, Valero A. Usefulness of the Nasal Allergen Provocation Test in the Diagnosis of Shellfish Allergy. J Investig Allergol Clin Immunol. 2022 Dec 15;32(6):460-470. doi: 10.18176/jiaci.0736. Epub 2022 Sep 7.
Results Reference
background

Learn more about this trial

NOVAPAK Nasal Packing in Shellfish Allergic Patients

We'll reach out to this number within 24 hrs